2024
Maia-Silva D., Cunniff P.J., Schier A.C., Skopelitis D., Trousdell M.C., Moresco P., Gao Y., Kechejian V., He X.Y., Sahin Y., Wan L., Alpsoy A., Liverpool J., Krainer A.R., Egeblad M., Spector D.L., Fearon D.T., Dos Santos C.O., Taatjes D.J., Vakoc C.R. (2024) Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. Nat Genet. Online first.
Wan L.*, Kral A.J.*, Voss D., Krainer A.R. (2024) Preclinical screening of splice-switching antisense oligonucleotides in PDAC organoids. Nucleic Acid Therapeutics. Online first.
He X.Y., Gao Y., Ng D., Michalopoulou E., George S., Adrover J.M., Sun L., Albrengues J., Daßler-Plenker J., Han X., Wan L., Wu X.S., Shui L.S., Huang Y.H., Liu B., Su C., Spector D.L., Vakoc C.R., Van Aelst L., Egeblad M. (2024) Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. Cancer Cell 11;42(3):474-486.e12.
2023
Islam M.R., Nagar P., Neetole S.T., Wan L.*, Rahman M.A.* (2023). RNA Splicing in Cancer and Targeted Therapies. Genes, 14(11), 2020.
Wan L., Lin K., Rahman M.A., Ishigami Y., Wang Z., Jensen M.A., Wilkinson J.E., Park Y., Tuveson D.A., Krainer A.R. (2023) Splicing factor SRSF1 promotes pancreatitis and KRASG12D-mediated pancreatic cancer. Cancer Discovery 13, 1678–1695.
2022 and earlier
Wan L.*, Deng M, Zhang H* (2022) SR Splicing Factors Promote Cancer via Multiple Regulatory Mechanisms. Genes 13, 1659.
Wan L., Lin K., Rahman M. A., Wang Z., Park Y., Tuveson D. A., Krainer, A. R. Abstract PR-011: Loss of compensatory feedback mechanism involving splicing factor SRSF1 accelerates KRASG12D-mediated pancreatic cancer initiation. Cancer Research 81, PR-011-PR-011.
Wan L., Yu W., Shen E., Sun W., Liu Y., Kong J., Wu Y., Han F., Zhang L., Yu T., Zhou Y., Xie S., Xu E., Zhang H., Lai M (2019) SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut 68, 118-129.
Zhu Y, Lu H, Zhang D, Li M, Sun X, Wan L., Yu D, Tian Y, Jin H, Lin A, Gao F, Lai M (2018) Integrated analyses of multi-omics reveal global patterns of methylation and hydroxymethylation and screen the tumor suppressive roles of HADHB in colorectal cancer. Clinical Epigenetics 10, 30.
Wan L., Kong J., Tang J., Wu Y., Xu E., Lai M., Zhang H (2016) HOTAIRM1 as a potential biomarker for diagnosis of colorectal cancer functions the role in the tumor suppressor. Journal of Cellular and Molecular Medicine 20, 2036-44.
Kong J., Sun W., Li C., Wan L., Wang S., Wu Y., Xu E., Zhang H., Lai M (2016) Long non-coding RNA LINC01133 inhibits epithelial–mesenchymal transition and metastasis in colorectal cancer by interacting with SRSF6. Cancer Letters 380, 476-484.
Cao H., Zhang J., Liu H., Wan L., Zhang H., Huang Q., Xu E., Lai M (2016) IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells. Oncotarget 7, 61183-61198.
Zhou D., Li Z., Yu D., Wan L., Zhu Y., Lai M., Zhang D (2015) Polymorphisms involving gain or loss of CpG sites are significantly enriched in trait-associated SNPs. Oncotarget 6, 39995-40004.
Yu D, Li Z, Gan M, Zhang H, Yin X, Tang S, Wan L., Tian Y, Zhang S, Zhu Y, Lai M, Zhang D (2015) Decreased expression of dual specificity phosphatase 22 in colorectal cancer and its potential prognostic relevance for stage IV CRC patients. Tumour biology 36(11), 8531–8535.
Cao H. Xu E., Liu H., Wan L., Lai M (2015) Epithelial–mesenchymal transition in colorectal cancer metastasis: A system review. Pathology - Research and Practice 211, 557-569.
Han C.*, Wan L.*, Ji H., Ding K., Huang Z., Lai Y., Peng S., Zhang Y (2014) Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors. European Journal of Medicinal Chemistry 77, 75-83.
Han C., Huang Z., Zheng C., Wan L., Lai Y., Peng S., Ding K., Ji H., Zhang Y (2013) Nitric oxide donating anilinopyrimidines: Synthesis and biological evaluation as EGFR inhibitors. European Journal of Medicinal Chemistry 66, 82-90.
Han C., Huang Z., Zheng C., Wan L., Zhang L., Peng S., Ding K., Ji H., Tian J., Zhang Y (2013) Novel hybrids of (phenylsulfonyl) furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer. Journal of Medicinal Chemistry 56, 4738-4748.